Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)
| 0.6058 Delayed Data As of Jun 24 |  -0.0679 / -10.45%Today’s Change | 0.58 Today|||52-Week Range 8.50 | -87.25% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Quarter Trend | |||||
|---|---|---|---|---|---|---|
| Quarter 3 2018 | Quarter 4 2018 | Quarter 1 2019 | Quarter 2 2019 | |||
| Assets | Cash | 14.5M | 22.5M | 85.6M | 25.4M | |
| Short Term Investment Cash | -6.0M | 7.9M | 63.2M | -58.7M | ||
| Cash & Short Term Investments | 64.7M | 74.5M | 123.7M | 105.5M | ||
| Receivables | Receivables | 2.4M | 300.0K | 0.00 | 0.00 | |
| Inventories | Inventories | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Current Assets | Other Current Assets | 3.2M | 1.9M | 3.1M | 4.4M | |
| Current Assets | 70.4M | 76.7M | 126.8M | 109.9M | ||
| Total Assets | Property, Plant and Equipment - Gross | -- | 1.8M | -- | -- | |
| Depreciation | -- | -752.0K | -- | -- | ||
| Other Assets | 49.0K | 50.0K | 50.0K | 50.0K | ||
| Total Assets | 71.3M | 77.7M | 128.5M | 117.5M | ||
| Liabilities | Accounts Payable | 1.1M | 663.0K | 3.2M | 2.7M | |
| Short Term Debt | 0.00 | 0.00 | 343.0K | 355.0K | ||
| Accrued Expenses | 4.6M | 6.9M | 7.1M | 8.0M | ||
| Other Current Liabilities | 4.6M | 6.9M | 7.2M | 8.1M | ||
| Other Liabilities | 7.5M | 10.2M | 11.8M | 13.0M | ||
| Total Liabilities | Long Term Debt | -- | 0.00 | 424.0K | 4.9M | |
| Other Liabilities | 81.0K | 72.0K | 0.00 | 0.00 | ||
| Total Liabilities | 7.6M | 10.3M | 12.2M | 17.9M | ||
| Equity | Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Preferred Stock | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Equity | 63.7M | 67.4M | 116.3M | 99.6M | ||
| Total Shareholder Equity | 63.7M | 67.4M | 116.3M | 99.6M | ||
| Share Information | Common Shares Outstanding | 22.1M | 24.1M | 28.8M | 28.8M | |
| Addtl. Info. | No data currently available for this section. | |||||
